The Latest Cardiac and Vascular News
VST-Bio’s Collaborators Present Preclinical Trial Results at the American Heart Association International Stroke Conference in Dallas. SAN DIEGO, Feb. 10, 2023 /PRNewswire/ — VST-Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from […]
New study utilizes Hyperfine, Inc. portable MRI system in monitoring brain injury and evaluating physiological impacts GUILFORD, Conn., Feb. 09, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first […]
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs). Clinical phase 1/2 study (LAPiS Study) will enrol 10 patients with advanced heart failure caused by ischaemic heart disease. Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today […]
LUND, Sweden, Feb 9, 2023 /PRNewswire/ – Syntach AB (“Syntach”) is pleased to announce that it has entered into a partnership agreement with Meditrial Europe Ltd (“Meditrial”) to support the clinical and regulatory strategies of Syntach’s innovative minimally invasive cardiac support system. […]
Abbott will gain an innovative, complementary solution in treating vascular disease through CSI’s leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow CSI’s offering will support Abbott’s ability to provide better care for patients with […]
With access to innovative healthcare technologies, clinicians can continue to provide exceptional care to local and surrounding communities and deliver on Quadruple Aim Amsterdam, the Netherlands and Cincinnati, Ohio, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health […]
CALGARY, AB, Feb. 9, 2023 /PRNewswire/ – Cardiovascular diseases affects over 3 million Canadians, and over 750, 000 Canadians are living with heart failure. Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 new Canadians are diagnosed with heart […]
Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; These Results Include an Unfavorable Impact of $0.39 Per Share related to 2022 Acquired IPR&D and Milestones Expense1 Delivers Full-Year […]
Funding to advance product development and initiate clinical experience of company’s next-generation technology for transseptal mitral valve replacement LOS GATOS, Calif., Feb. 9, 2023 /PRNewswire/ — Tioga Cardiovascular, a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the first […]
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. […]
